Smart Nanocarriers for the Treatment of Retinal Diseases

ACS Appl Bio Mater. 2024 Apr 15;7(4):2070-2085. doi: 10.1021/acsabm.3c01289. Epub 2024 Mar 15.

Abstract

Retinal diseases, such as age-related macular degeneration, diabetic retinopathy, and retinoblastoma, stand as the leading causes of irreversible vision impairment and blindness worldwide. Effectively administering drugs for retinal diseases poses a formidable challenge due to the presence of complex ocular barriers and elimination mechanisms. Over time, various approaches have been developed to fabricate drug delivery systems for improving retinal therapy including virus vectors, lipid nanoparticles, and polymers. However, conventional nanocarriers encounter issues related to the controllability, efficiency, and safety in the retina. Therefore, the development of smart nanocarriers for effective or more invasive long-term treatment remains a desirable goal. Recently, approaches have surfaced for the intelligent design of nanocarriers, leveraging specific responses to external or internal triggers and enabling multiple functions for retinal therapy such as topical administration, prolonged drug release, and site-specific drug delivery. This Review provides an overview of prevalent retinal pathologies and related pharmacotherapies to enhance the understanding of retinal diseases. It also surveys recent developments and strategies employed in the intelligent design of nanocarriers for retinal disease. Finally, the challenges of smart nanocarriers in potential clinical retinal therapeutic applications are discussed to inspire the next generation of smart nanocarriers.

Keywords: ophthalmology; posterior segment drug delivery; retinal disease; smart nanocarriers; stimuli-response.

Publication types

  • Review

MeSH terms

  • Drug Delivery Systems
  • Humans
  • Pharmaceutical Preparations
  • Retinal Diseases* / drug therapy

Substances

  • Pharmaceutical Preparations